Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Countries and organisations
Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.
Free access · No subscription for research tools or data exports
Explore registry geography and organisations
13 trials match this view; 13 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 530 across 13 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Countries with reported trial locations
Sponsors recorded in this index
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot StudyParkinson Disease · Depression · Anxiety | Joshua Woolley, MD, PhD PHASE2 | Completed Registry updated 2026-09-03 | 12 ACTUAL | 2021-08-15 2024-12-31 2024-12-31 | |
| Processing Intergenerational Trauma With Psilocybin-Assisted TherapyPsychological Stress · Depression · Anxiety | Rachel Yehuda PHASE2 | Recruiting Registry updated 2026-08-13 | 100 ESTIMATED | 2026-08-28 2029-05-31 2030-01-02 | |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsDepression · Anxiety · Cancer | M.D. Anderson Cancer Center PHASE2 | Recruiting Registry updated 2026-08-12 | 20 ESTIMATED | 2025-05-23 2027-03-31 2029-03-31 | |
| A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionAnxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm | University of Washington PHASE2 | Active, not recruiting Registry updated 2026-07-31 | 18 ESTIMATED | 2026-05-19 2026-12-01 2027-05-01 | |
| A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyDepression · Anxiety · Major Depressive Disorder | Ohio State University PHASE2 | Recruiting Registry updated 2026-07-23 | 40 ESTIMATED | 2026-08-01 2028-09 2028-11 | |
| A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of DepressionDepression · Anxiety | University of Washington PHASE2 | Not yet recruiting Registry updated 2026-05-04 | 72 ESTIMATED | 2026-06 2027-12 2028-07 | |
| Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress | University Hospital, Basel, Switzerland PHASE2 | Recruiting Registry updated 2026-04-29 | 60 ESTIMATED | 2024-06-09 2027-09 2028-05 | |
| Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyTransdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms · PTSD · Substance Use · Substance Use Disorder (SUD) · OCD | Yale University PHASE1 | Recruiting Registry updated 2026-03-11 | 50 ESTIMATED | 2024-10-17 2027-12 2027-12 | |
| Effects of Psilocybin in Advanced-Stage Cancer Patients With AnxietyAnxiety | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center PHASE1, PHASE2 | Completed Registry updated 2025-03-13 | 12 ACTUAL | 2004-04 2008-12 2008-12 | |
| A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use DisorderAlcohol Use Disorder · Alcohol Dependence · Depression · Anxiety | University of Sydney PHASE2 | Unknown status Registry updated 2024-06-10 | 90 ESTIMATED | 2024-09 2025-07 2025-12 | |
| Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.Anxiety · Stage IV Melanoma | Multidisciplinary Association for Psychedelic Studies PHASE2 | Withdrawn Registry updated 2023-12-26 | 0 ACTUAL | 2012-01 2013-04 2013-06 | |
| Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyMood Disturbance · Mood Change · Sleep Disturbance · Drug Effect · Psychedelic Experiences · Health, Subjective · Psilocin Toxicity · Psilocybin Toxicity · Psilocybin Causing Adverse Effects in Therapeutic Use · Anxiety | Optimi Health Corporation EARLY_PHASE1 | Withdrawn Registry updated 2023-03-20 | 0 ACTUAL | 2023-01 2023-08 2023-12 | |
| Psychopharmacology of Psilocybin in Cancer PatientsDepressive Symptoms · Anxiety · Cancer | Johns Hopkins University PHASE2 | Completed Registry updated 2018-07-19 | 56 ACTUAL | 2007-04 2014-12 2016-12 |
Reported research facilities
University of California, San FranciscoSan Francisco, California, United States
The Parsons Research Center for Psychedelic HealingNew York, New York, United States
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States
Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States
The Ohio State University Department of PsychiatryColumbus, Ohio, United States
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland
Spital Uster AG, Division of Internal MedicineUster, Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland
Connecticut Mental Health Center - Yale School of MedicineNew Haven, Connecticut, United States
Harbor-UCLA Medical CenterTorrance, California, United States
Mount Sinai Comprehensive Cancer CenterMiami Beach, Florida, United States
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore, Maryland, United States
This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.